Aligos Therapeutics
Clinical trials sponsored by Aligos Therapeutics, explained in plain language.
-
New pill challenges standard hepatitis b treatment in major trial
Disease control Recruiting nowThis study is testing if a new daily pill, ALG-000184, is better than the standard drug tenofovir at controlling the Hepatitis B virus. It will involve about 200 adults with chronic Hepatitis B who are not currently on treatment. Participants will take one of the two pills for 48…
Phase: PHASE2 • Sponsor: Aligos Therapeutics • Aim: Disease control
Last updated Apr 02, 2026 03:57 UTC
-
First safety check for hepatitis b drug in vulnerable kidney patients
Disease control Recruiting nowThis early-stage study is checking how a new hepatitis B drug, pevifoscorvir sodium, is processed by the body in people with reduced kidney function. Researchers will give a single dose to about 30 participants—some with kidney impairment and some with healthy kidneys—and closely…
Phase: PHASE1 • Sponsor: Aligos Therapeutics • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Early safety check for hepatitis b drug in people with liver problems
Knowledge-focused Recruiting nowThis early-stage study aims to understand how a new hepatitis B drug is processed in people with moderate liver impairment compared to those with normal liver function. It involves 16 participants who will receive a single dose of the drug. The main goal is to measure drug levels…
Phase: PHASE1 • Sponsor: Aligos Therapeutics • Aim: Knowledge-focused
Last updated Apr 02, 2026 03:55 UTC